Company intelligence / Profile preview

Glycorex Transplantation

Ownership: Private
Development stage: Other

Overview

Glycosorb® ABO has enabled over 7,000 blood group-incompatible transplants worldwide with excellent short and long-term outcomes comparable to compatible transplants. The company’s universal plasma product has been CE-marked and launched in Europe. Early-stage development for autoimmune disease applications such as rheumatoid arthritis is ongoing

Therapeutic areas: PulmonologyHematologyGastroenterologyNephrologyImmunologyCardiovascular
Modalities: DeviceBiologic (extracorporeal immunoadsorption columns)
Industry: Therapeutic Medical Devices

Partnerships

Collaboration with a leading European research institute on the RA programdistribution partners globallyno major pharma partnerships disclosed

Beyond the preview

Go deeper on Glycorex Transplantation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glycorex Transplantation.

Explore the full profile